And next, I will explain the second quarter results details. First, the FYÂ'2025 second quarter Honda Group six-month unit sales. Motor cycle business at 10,382,000 units, due mainly to year-on-year increase in Asia. Automobile business, 1,779,000 units mainly due to drop in Asia, in particular, China. Profit before income taxes declined by 137.3 billion yen due to a decline in unit sales in China, decrease in equity method profit due to drop in domestic-related companies' profit, and appraisal loss of fore ...

DZS, Inc. (OTC:DZSI) Q3 2024 Earnings Conference Call November 6, 2024 11:00 AM ET Company Participants Geoff Burke - SVP, Marketing & IR Charles Vogt - President, CEO & Director Brian Chesnut - Interim CFO Conference Call Participants Ryan Koontz - Needham Operator Good day, ladies and gentlemen. Thank you for standing by. My name is John, and I'll be your conference operator today. At this time, I would like to welcome everyone to the DZS Third Quarter 2024 Financial Results Conference Call. [Operator In ...

Ashford Hospitality Trust, Inc. (NYSE:AHT) Q3 2024 Earnings Conference Call November 6, 2024 11:00 AM ET Company Participants Deric Eubanks - Chief Financial Officer Stephen Zsigray - President and Chief Executive Officer Chris Nixon - Executive Vice President and Head-Asset Management Conference Call Participants Jonathan Jenkins - Oppenheimer Michael Bellisario - Baird Operator Hello and welcome to the Ashford Hospitality Trust's Third Quarter 2024 Results Conference Call. All lines have been placed on mu ...

Hamilton Lane Incorporated (NASDAQ:HLNE) Q2 2025 Results Conference Call November 6, 2024 11:00 AM ET Company Participants John Oh - Head, Shareholder Relations Erik Hirsch - Co-Chief Executive Officer Jeff Armbrister - Chief Financial Officer Conference Call Participants Ken Worthington - JPMorgan Alex Blostein - Goldman Sachs Michael Cyprys - Morgan Stanley Mike Brown - Wells Fargo Securities Operator Good morning, ladies and gentlemen, and welcome to the Hamilton Lane Fiscal Second Quarter Earnings Confe ...

Atlanta Braves Holdings, Inc. (NASDAQ:BATRA) Q3 2024 Results Conference Call November 6, 2024 10:00 AM ET Company Participants Jennifer Giglio - Senior Vice President of Communications Terry McGuirk - President and CEO Derek Schiller - President & CEO, Atlanta National League Baseball Club Jill Robinson - Executive VP, CFO & Treasurer Conference Call Participants Ben Swinburne - Morgan Stanley Barton Crockett - Rosenblatt Securities David Joyce - Seaport Research Partners Matthew Harrigan - Benchmark Operat ...

Conduent Incorporated (NASDAQ:CNDT) Q3 2024 Results Conference Call November 6, 2024 9:00 AM ET Company Participants Giles Goodburn - Vice President, Investor Relations Cliff Skelton - President and Chief Executive Officer Steve Wood - Chief Financial Officer Conference Call Participants Pat McCann - NOBLE Capital Markets Marc Riddick - Sidoti & Company Chris Sakai - Singular Research Operator Greetings, and welcome to the Conduent Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a re ...

Mogo Inc (NASDAQ:MOGO) Q3 2024 Results Conference Call November 6, 2024 12:00 PM ET Company Participants Craig Armitage - IR David Feller - Founder, CEO & Chairman Greg Feller - President, CFO & Director Conference Call Participants Adhir Kadve - Eight Capital Scott Buck - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Mogo Q3 Earnings Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct the question and answer se ...

Start Time: 09:00 January 1, 0000 10:32 AM ET The Scotts Miracle-Gro Company (NYSE:SMG) Q4 2024 Earnings Call November 06, 2024, 09:00 AM ET Company Participants Jim Hagedorn - Chairman, President and CEO Matt Garth - EVP, CFO and CAO Nate Baxter - EVP and COO Chris Hagedorn - EVP and Division President, Hawthorne Gardening Company Aimee DeLuca - SVP, IR Conference Call Participants Jon Andersen - William Blair Joe Altobello - Raymond James William Carter - Stifel Peter Grom - UBS Chris Carey - Wells Fargo ...

Financial Data and Key Metrics - The company ended Q3 2024 with approximately $131 million in cash, cash equivalents, and marketable securities, compared to $132 million as of December 31, 2023 [19] - Net proceeds from the issuance of common shares under the at-the-market offering program were approximately $44 million in the first half of 2024, offset by $54.5 million of cash used in operations [19] - The company expects its 2024 cash burn to range between $63 million and $67 million, with sufficient cash runway to fund operations into Q4 2026 [20] Business Line Data and Key Metrics - The IM-PROVE I clinical trial showed that 33% of patients in Cohort A1 achieved sustained surface antigen loss at 24 weeks post-treatment, with 67% of patients with baseline surface antigen <1,000 IU/mL maintaining surface antigen loss [9][10] - In the IM-PROVE II trial, 95% of patients achieved surface antigen levels <100 IU/mL prior to dosing with VTP-300 or placebo, with more patients maintaining thresholds <100 or <10 IU/mL versus placebo [12] - AB-101, the oral small molecule PD-L1 checkpoint inhibitor, demonstrated dose-dependent receptor occupancy in Phase Ia/Ib trials, with 7 out of 8 subjects in the 25-milligram cohort showing >70% receptor occupancy [16] Market Data and Key Metrics - Chronic HBV affects over 250 million people globally, with current treatments offering a functional cure rate of less than 10% [6][25] - The company is focused on developing a functional cure for HBV, aiming for a 20% functional cure rate, which would significantly reduce the risk of liver cirrhosis and hepatocellular carcinoma [7][25] Company Strategy and Industry Competition - The company is advancing imdusiran into a Phase IIb clinical trial as a cornerstone in a potential HBV functional cure treatment regimen, combining it with immune modulators like interferon and VTP-300 [13] - AB-101 is being developed to enhance HBV-specific immune responses in combination with imdusiran, with preliminary data from HBV patients expected in the first half of 2025 [14][17] - The company is involved in litigation with Moderna and Pfizer/BioNTech regarding LNP intellectual property, with trial dates set for September 2025 and December 2024, respectively [18] Management Commentary on Operating Environment and Future Outlook - The company remains committed to transforming the HBV treatment landscape and providing hope to millions of patients worldwide [49] - Management is optimistic about the upcoming data presentations at AASLD, including updates from the IM-PROVE I trial and preliminary data from the nivolumab arm of the IM-PROVE II trial [21] Other Important Information - The company has achieved all of its second-half milestones, including reporting multiple ascending dose data from healthy subjects in the AB-101-001 trial [21] Q&A Session Summary Question: Functional Cure Data Expectations - The company has not presented functional cure data for imdusiran yet but aims for a 20% functional cure rate as a meaningful benchmark [24][25] - All subjects in the IM-PROVE I study received at least 4 doses of imdusiran, with Cohort A1 continuing imdusiran during interferon treatment, while Cohort A2 received only interferon after the initial 4 doses [26] Question: Denominator for Functional Cure Calculation - The denominator for functional cure in Cohort A1 is 12 patients, with 33% achieving surface antigen loss [29] - Patients with baseline surface antigen <1,000 IU/mL showed a 67% surface antigen loss rate, aligning with industry trends [30] Question: AB-101 Data and Study Design - Preliminary data from AB-101 in HBV patients is expected in the first half of 2025, with biomarker collection ongoing to assess receptor occupancy and immune response [39][40] - The company plans to combine AB-101 with imdusiran as quickly as possible, following monotherapy evaluation [42] Question: IM-PROVE II Data at AASLD - The AASLD presentation will focus on Group C of the IM-PROVE II study, which includes low-dose nivolumab [43] Question: Litigation Update - The claim construction hearing for the Pfizer/BioNTech lawsuit is scheduled for December 18, 2024, with a trial date for the Moderna case set for September 24, 2025 [18][45] Question: Cash Runway and ATM Program - The company's cash runway into Q4 2026 does not include any expected proceeds from the ATM program [48]

Eos Energy Enterprises, Inc. (NASDAQ:EOSE) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Liz Higley - Director, Investor Relations Joe Mastrangelo - Chief Executive Officer Nathan Kroeker - Chief Financial Officer Conference Call Participants Thomas Boyes - TD Cowan Martin Malloy - Johnson Rice & Company Stephen Gengaro - Stifel Financial Corp. Joseph Osha - Guggenheim Securities Chip Moore - ROTH Capital Partners Operator Good morning and welcome to the EOS Energy Enterp ...